Autonomix Medical, Inc. announced on July 22, 2025, that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants. This transaction generated approximately $2.5 million in gross proceeds for the company.
The agreements involved the exercise (or prepayment of the exercise price) of warrants to purchase up to an aggregate of 1,477,596 shares of common stock. These warrants were originally issued in connection with previous financing activities.
This capital infusion provides additional funding for Autonomix Medical as it continues to advance its precision nerve-targeted treatments. The proceeds will support ongoing clinical development, research, and general corporate purposes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.